



1632

PATENT APPLICATION
File No: 00-100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Charles E. Hart, Stavros Topouzis
Serial No. : 10/039,847
Group Art Unit : 1632
Examiner : Chen, L.
Filed : October 26, 2001
For : COMPOSITIONS AND METHODS FOR IMPROVING KIDNEY
FUNCTION
Date Submitted : January 24, 2003

RECEIVED

FEB 05 2003

TECH CENTER 1600/2900

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application. The fee required to be filed with the accompanying amendment has been calculated as shown below:

CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	8	-23	0	\$9.00	\$000.00
Independent	1	- 2	0	\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
				Total	\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Gary E. Parker
Registration No. 31,648



#MIA
5/5/03

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: BOX NON-FEE AMENDMENT, Commissioner for Patents, Washington, D.C. 20231.

Jan. 24, 2002

Date

Gary E. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Charles E. Hart, Stavros Topouzis
Serial No. : 10/039,847
Filed : October 26, 2001
For : COMPOSITIONS AND METHODS FOR IMPROVING KIDNEY FUNCTION

Examiner : Chen, L.
Art Unit : 1632
Docket No. : 00-100
Date : January 24, 2003

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

FEB 05 2003

TECH CENTER 1600/2900

Response to Restriction Requirement

Sir:

Please amend the above-identified patent application as follows:

In the Claims:

Please cancel claims 1-12 and 21-23 without prejudice.

Please replace claim 13 with the following amended claim:

13. (amended) A method of enhancing proliferation or survival of kidney tubule epithelial cells or epithelial cell precursors in a mammal, comprising administering to the mammal a composition comprising a therapeutically effective amount of a zvegf4 protein, in combination with a pharmaceutically acceptable delivery vehicle, wherein the zvegf4 protein is a disulfide-bonded dimer of two polypeptide chains, each of said chains consisting of residues x - y of SEQ ID NO:2, inclusive, wherein the protein is optionally glycosylated, and wherein:

Q1